Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06900296 · ClinicalTrials.gov registry record
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
A clinical trial, sponsored by Indiana University.
- Not yet
- Registry status
- 100
- Enrollment target
NCT06900296: Clinical Trial study, sponsored by Indiana University.
NCT06900296 is a clinical trial that has not yet begun recruiting, run by Indiana University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06900296 has not yet begun recruiting, sponsored by Indiana University.
- NOT YET RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.
Primary Outcome
Including cytokines, chemokines, growth factors, and other relevant immunologic molecules from blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-05 |
| Est. Completion | 2029-04 |
What is known before NCT06900296 opens enrollment
NCT06900296 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06900296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06900296 about?
NCT06900296 is a clinical study titled "ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)". This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.
What is the current status of trial NCT06900296?
This trial is currently not yet recruiting. The enrollment target is 100 participants. The study started on 2026-05. Estimated completion is 2029-04.
Who is sponsoring clinical trial NCT06900296?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia